For the quarter ending 2025-09-30, SANA made $44,878K in revenue. -$42,152K in net income. Net profit margin of -93.93%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Impairment of long-lived assets | - | 44,611 | ||
| Research and development | 30,106 | 29,761 | ||
| Research and development related success payments and contingent consideration | 3,124 | 10,262 | ||
| General and administrative | 10,285 | 10,341 | ||
| Total operating expenses | 43,515 | 94,975 | ||
| Loss from operations | -43,515 | -94,975 | ||
| Interest income, net | 1,003 | 577 | ||
| Other income (expense), net | 360 | 598 | ||
| Net loss | -42,152 | -93,800 | ||
| Basic earnings (loss) per common share | -0.16 | -0.39 | ||
| Diluted earnings (loss) per common share | -0.16 | -0.39 | ||
| Weighted-average number of common shares - basic | 260,494,000 | 238,409,000 | ||
| Weighted-average number of common shares - diluted | 260,494,000 | 238,409,000 | ||
Sana Biotechnology, Inc. (SANA)
Sana Biotechnology, Inc. (SANA)